Price
CHART BY
Frequently asked questions
What is Fulcrum's market capitalization?
The market capitalization of Fulcrum is $522.15M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Fulcrum?
Fulcrum's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.181. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Fulcrum's stock?
Currently, 10 analysts cover Fulcrum's stock, with a consensus target price of $19.00. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Fulcrum?
Fulcrum's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$83.47M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Fulcrum?
Fulcrum has a free cash flow of -$60.38M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Fulcrum have, and what sector and industry does it belong to?
Fulcrum employs approximately 55 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Fulcrum's shares?
The free float of Fulcrum is 56.81M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $522.15M
- EPS (TTM)
- -$1.181
- Free Float
- 56.81M
- EBITDA (TTM)
- -$83.47M
- Free Cashflow (TTM)
- -$60.38M
Pricing
- 52W span
- $3.48$15.50
Analyst Ratings
The price target is $19.00 and the stock is covered by 10 analysts.
Buy
8
Hold
1
Sell
1
Information
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.
- Employees
- 55
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- FULC
Fundamentals & EOD data from FactSet